Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
Non-small cell lung carcinoma (NSCLC) is the major cause of cancer-associated mortality. Identification of rearrangements in anaplastic lymphoma kinase (ALK) gene is an effective instrument for more effective targeted therapy of NSCLC using ALK inhibitors dramatically raising progression-free surviv...
Main Authors: | Elena Poddubskaya, Alexey Bondarenko, Alexander Boroda, Evgenia Zotova, Alex Glusker, Svetlana Sletina, Luidmila Makovskaia, Philipp Kopylov, Marina Sekacheva, Alexey Moisseev, Madina Baranova |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01026/full |
Similar Items
-
Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report
by: Cai C, et al.
Published: (2020-08-01) -
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
by: Stephen P. Ducray, et al.
Published: (2019-07-01) -
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01) -
Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
by: Peng L, et al.
Published: (2021-05-01) -
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
by: Ali R, et al.
Published: (2019-02-01)